- 全部删除
您的购物车当前为空
Bemarituzumab是一种新型人源化IgG1单抗,靶向xGFR2b。Bemarituzumab可防止FGFR2b与 FGF的结合并活化。Bemarituzumab在癌症研究中的潜在应用。

为众多的药物研发团队赋能,
让新药发现更简单!
Bemarituzumab是一种新型人源化IgG1单抗,靶向xGFR2b。Bemarituzumab可防止FGFR2b与 FGF的结合并活化。Bemarituzumab在癌症研究中的潜在应用。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,660 | In stock | |
| 5 mg | ¥ 4,990 | In stock | |
| 10 mg | ¥ 6,880 | In stock | |
| 25 mg | ¥ 9,870 | In stock | |
| 50 mg | ¥ 13,800 | In stock | |
| 100 mg | ¥ 18,600 | In stock |
Bemarituzumab 相关产品
| 产品描述 | Bemarituzumab is a novel humanized IgG1 monoclonal antibody targeting FGFR2b. Bemarituzumab prevents FGFR2b from binding to FGF and activation. Potential applications of Bemarituzumab in cancer research. |
| 别名 | 贝玛妥珠单抗, FPA144 |
| 分子量 | 144 kDa |
| CAS No. | 1952272-74-0 |
| 颜色 | Transparent |
| 物理性状 | Liquid |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容